The invention relates to a method of producing carbonyl compounds, more particularly C.sub.2-C.sub.4 ketones and aldehydes. The method is based on the gas-phase oxidation by nitrous oxide of C.sub.2-C.sub.4 alkane-olefin mixtures, such as a butane-butylene fraction or a propane-propylene fraction, obtained by thermal and/or catalytic cracking, to produce C.sub.2-C.sub.4 ketones and aldehydes. The process is carried out under continuous flow conditions at a temperature of 300-550° C. and pressure of 1-100 atm, without prior isolation of individual olefins from the fractionation products and in the absence of a catalyst. The process provides for high productivity, high overall selectivity for ketones and aldehydes, and explosion-safe operation.

The invention relates to a method of producing carbonyl compounds, more particularly C.sub.2-C.sub.4 ketones and aldehydes. The method is based on the gas-phase oxidation by nitrous oxide of C.sub.2-C.sub.4 alkane-olefin mixtures, such as a butane-butylene fraction or a propane-propylene fraction, obtained by thermal and/or catalytic cracking, to produce C.sub.2-C.sub.4 ketones and aldehydes. The process is carried out under continuous flow conditions at a temperature of 300-550° C. and pressure of 1-100 atm, without prior isolation of individual olefins from the fractionation products and in the absence of a catalyst. The process provides for high productivity, high overall selectivity for ketones and aldehydes, and explosion-safe operation.

Disclosed is a method of preparing 1,3-butadiene and methyl ethyl ketone from 2,3-butanediol, including: a) providing a plurality of adiabatic reactors, which include a catalyst bed for dehydrating 2,3-butanediol, without a heat transfer medium, and are connected in series; b) introducing a stream including 2,3-butanediol at a temperature ranging from 200° C. to 400° C. into a first adiabatic reactor among the plurality of adiabatic reactors; c) dehydrating the 2,3-butanediol so as to be converted into 1,3-butadiene and methyl ethyl ketone and discharging a product stream including 1,3-butadiene and methyl ethyl ketone; d) heating the discharged product stream to 200° C. to 400° C.; and e) introducing the heated product stream into a second adiabatic reactor so that 2,3-butanediol is further dehydrated and converted into 1,3-butadiene and methyl ethyl ketone and then discharging the product stream including 1,3-butadiene and methyl ethyl ketone.

Disclosed is a method of preparing 1,3-butadiene and methyl ethyl ketone from 2,3-butanediol, including: a) providing a plurality of adiabatic reactors, which include a catalyst bed for dehydrating 2,3-butanediol, without a heat transfer medium, and are connected in series; b) introducing a stream including 2,3-butanediol at a temperature ranging from 200° C. to 400° C. into a first adiabatic reactor among the plurality of adiabatic reactors; c) dehydrating the 2,3-butanediol so as to be converted into 1,3-butadiene and methyl ethyl ketone and discharging a product stream including 1,3-butadiene and methyl ethyl ketone; d) heating the discharged product stream to 200° C. to 400° C.; and e) introducing the heated product stream into a second adiabatic reactor so that 2,3-butanediol is further dehydrated and converted into 1,3-butadiene and methyl ethyl ketone and then discharging the product stream including 1,3-butadiene and methyl ethyl ketone.

The present invention provides novel Ruthenium-based transition metal complex catalysts comprising specific ligands, their preparation and their use in hydrogenation processes. Such complex catalysts are inexpensive, thermally robust, and olefin selective.

The present invention provides novel Ruthenium-based transition metal complex catalysts comprising specific ligands, their preparation and their use in hydrogenation processes. Such complex catalysts are inexpensive, thermally robust, and olefin selective.

The present invention relates to processes for the preparation of empagliflozin. In particular, the present invention relates to the preparation of empagliflozin and intermediates thereof. The present invention also relates to co-crystal of empagliflozin and amino acid and amorphous form of empagliflozin.

The present invention relates to processes for the preparation of empagliflozin. In particular, the present invention relates to the preparation of empagliflozin and intermediates thereof. The present invention also relates to co-crystal of empagliflozin and amino acid and amorphous form of empagliflozin.

A non-aqueous electrolyte secondary cell provided with: a positive electrode that has a positive electrode active material; a negative electrode; and a non-aqueous electrolyte. The positive electrode active material contains a lithium composite oxide containing Ni, and the non-aqueous electrolyte contains a non-aqueous solvent containing a fluorinated chain carboxylic acid ester and an organochlorine compound. The organochlorine compound is represented by general formula CF.sub.3CH.sub.2CO—CClR.sub.1R.sub.2 (where in the formula, R.sub.1 and R.sub.2 are respectively independent, and are selected from a hydrogen, a halogen, a C1-2 alkyl group, or a C1-2 halogenated alkyl group).

A non-aqueous electrolyte secondary cell provided with: a positive electrode that has a positive electrode active material; a negative electrode; and a non-aqueous electrolyte. The positive electrode active material contains a lithium composite oxide containing Ni, and the non-aqueous electrolyte contains a non-aqueous solvent containing a fluorinated chain carboxylic acid ester and an organochlorine compound. The organochlorine compound is represented by general formula CF.sub.3CH.sub.2CO—CClR.sub.1R.sub.2 (where in the formula, R.sub.1 and R.sub.2 are respectively independent, and are selected from a hydrogen, a halogen, a C1-2 alkyl group, or a C1-2 halogenated alkyl group).